Reaction

Bone Marrow Transplant reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,863 reports · 52 co-occurring drugs

As of the last recalculation, Bone Marrow Transplant appears in 1,863 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is VENETOCLAX (PRR 57.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Venetoclax	272	57.6	57.9
Deferasirox	104	46.4	46.5
Eculizumab	135	29.8	29.9
Dasatinib	69	21.5	21.5
Daratumumab	71	20.6	20.6
Atovaquone	13	18.2	18.2
Posaconazole	26	18.1	18.1
Imatinib Mesylate	44	18.0	18.1
Fludarabine Phosphate	57	16.7	16.7
Busulfan	23	16.5	16.5
Posaconazole Delayed-Release	16	16.4	16.4
Azacitidine For	26	16.2	16.2
Valproate Sodium	29	15.9	15.9
Thiotepa	13	15.3	15.3
Phenytoin	25	13.6	13.6
Voxelotor	24	12.1	12.1
Azacitidine	31	11.9	11.9
Ursosiol	20	11.6	11.6
Voriconazole	30	11.2	11.2
Bortezomib	80	10.4	10.4
Voriconazole Injection	20	10.4	10.4
Ursodiol	20	10.4	10.4
Imatinib	16	10.2	10.2
Dronabinol	7	9.8	9.8
Daspone	8	9.2	9.2
Dapsone Gel, 5%	8	9.2	9.2
Filgrastim	30	9.0	9.0
Cytarabine	47	8.9	8.9
Cyclosporine	84	8.8	8.8
Ibrutinib	61	8.7	8.7
Dapsone	8	8.4	8.4
Acyclovir	82	8.3	8.3
Hydroxyurea	15	8.0	8.0
Melphalan Hydrochloride	17	7.6	7.6
Thalidomide	24	7.4	7.4
Cyclophosphamide Injection, Solution	105	7.0	7.0
Cyclophosphamide	105	7.0	7.0
Cyclophosphamide For Injection	105	7.0	7.0
Anti-Thymocyte Globulin (Rabbit)	5	6.9	6.9
Brentuximab Vedotin	6	6.6	6.6
Etoposide	42	6.5	6.5
Avapritinib	7	6.5	6.5
Ruxolitinib	39	6.2	6.2
Sorafenib	11	5.9	5.9
Bleomycin Sulfate	5	5.4	5.4
Blinatumomab	5	5.4	5.4
Micafungin Sodium	4	5.3	5.3
Daptomycin	4	4.9	4.9
Ravulizumab	5	4.1	4.1
Bosutinib	3	3.7	3.7
Romiplostim	5	3.7	3.7
Eltrombopag Olamine	7	3.4	3.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.